AstraZeneca to acquire US biopharma company CinCor Pharma for $1.8bn
AstraZeneca has agreed to acquire CinCor Pharma for a transaction value of around $1.8 billion, which includes an upfront cash payment of about $1.3 billion, ... Read More
AstraZeneca and Imperial spin-off VaxEquity enter into saRNA partnership
AstraZeneca has signed a collaboration deal with VaxEquity, a spin-off of Imperial College London, for discovering, developing, and commercializing the latter’s self-amplifying RNA (saRNA) therapeutics ... Read More
AstraZeneca’s Forxiga wins approval in China for heart failure treatment
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular ... Read More
AstraZeneca gets BRILINTA FDA approval for reducing risk of stroke in acute ischemic stroke or high-risk transient ischemic attack
BRILINTA FDA approval : AstraZeneca has bagged approval for BRILINTA (ticagrelor) from the US Food and Drug Administration for its use in reducing the risk ... Read More
AstraZeneca gets FDA breakthrough status for Farxiga in CKD
AstraZeneca has been granted breakthrough therapy designation (BTD) for Farxiga (dapagliflozin) from the US Food and Drug Administration (FDA) for the treatment of patients with ... Read More
AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics
Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The ... Read More
COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response
COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001 clinical trial showed the ChAdOx1 nCoV-19 vaccine ... Read More
Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI
AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) ... Read More
Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle
Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma ... Read More